Urso

Urso Bio is a biotechnology company that was established to develop advanced therapies for chronic liver diseases, with a primary focus on liver fibrosis and cirrhosis. The company utilized RNA interference (RNAi) technology, specifically small interfering RNAs (siRNAs), to target and inhibit the production of collagen in the liver, thereby slowing or reversing fibrotic scarring. Originating from research at the University of California, Davis, Urso Bio sought to provide a disease-modifying treatment for patients with limited options for end-stage liver disease. Its approach represented a potential breakthrough in hepatology by addressing the underlying mechanisms of fibrotic progression rather than just managing symptoms. Although the company showed promise in early-stage research, it is currently considered inactive.